Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 13/20 | 0.61 |
| ▸ | DPP8 | Q6V1X1 | 9/20 | 0.61 |
| ▸ | DPP9 | Q86TI2 | 8/20 | 0.61 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.61 |
| ▸ | FAP | Q12884 | 4/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | PREP | P48147 | 2/20 | 0.41 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20484694 | 1.00 | DPP4 (0.61) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL30729252 | 1.00 | DPP4 (0.61) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL30729264 | 1.00 | DPP4 (0.61) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL4433716 | 1.00 | DPP4 (0.61) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL4433719 | 1.00 | DPP4 (0.61) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL4432649 | 0.89 | ATM (0.56) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL4432643 | 0.89 | ATM (0.56) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL4441243 | 0.87 | ATM (0.61) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL15756825 | 0.87 | ATM (0.61) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL4441246 | 0.87 | ATM (0.61) | DPP4DPP8DPP9DPP7FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336654-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | Universität Zürich (CH) | 2024-10-10 | — | — | US | claimed |
| EP-4380689-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | Basilea Pharmaceutica International AG, Allschwil (CH) | 2024-06-12 | — | — | EP | claimed |
| CN-118043339-A | Antimicrobial peptidomimetics | 巴斯利尔药物阿尔施维尔国际股份公司 | 2024-05-14 | — | — | CN | claimed |
| EP-4214221-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | Spexis AG (CH) | 2023-07-26 | — | — | EP | claimed |
| EP-4214220-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | Spexis AG (CH) | 2023-07-26 | — | — | EP | claimed |
| WO-2023012319-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | SPEXIS AG (CH) | 2023-02-09 | — | — | WO | claimed |
| WO-2022028737-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | POLYPHOR AG (CH) | 2022-02-10 | — | — | WO | claimed |
| US-20240336654-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | Universität Zürich (CH) | 2024-10-10 | — | — | US | disclosed |
| CN-118043339-A | Antimicrobial peptidomimetics | 巴斯利尔药物阿尔施维尔国际股份公司 | 2024-05-14 | — | — | CN | disclosed |
| WO-2024029613-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF MUTANT KRAS PROTEIN | アステラス製薬株式会社 | 2024-02-08 | — | — | WO | disclosed |
| EP-4214221-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | Spexis AG (CH) | 2023-07-26 | — | — | EP | disclosed |
| EP-4214220-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | Spexis AG (CH) | 2023-07-26 | — | — | EP | disclosed |
| WO-2023012319-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | SPEXIS AG (CH) | 2023-02-09 | — | — | WO | disclosed |
| WO-2022028737-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | POLYPHOR AG (CH) | 2022-02-10 | — | — | WO | disclosed |
| EP-3341007-B1 | MALT1 INHIBITORS AND USES THEREOF | UNIV CORNELL (US) | 2020-12-23 | — | — | EP | disclosed |
| US-10711036-B2 | MALT1 inhibitors and uses thereof | CORNELL UNIVERSITY (US) | 2020-07-14 | — | — | US | disclosed |
| US-20180251489-A1 | MALT1 INHIBITORS AND USES THEREOF | Cornell University Cornell Center for Technology Enterprise & Commercialization (CCTEC) (US) | 2018-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251489-A1 | MALT1 INHIBITORS AND USES THEREOF | MALT1, BCL3, BCL6 | DPP4 2275/4885DPP8 1924/4885DPP9 2057/4885 |
| US-10711036-B2 | MALT1 inhibitors and uses thereof | MALT1, BCL3, BCL6 | DPP4 2242/4885DPP8 1846/4885DPP9 1990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.